Pharmaceutical Research

, Volume 20, Issue 8, pp 1284–1292

Novel Polyester-Polysaccharide Nanoparticles

  • Caroline Lemarchand
  • Patrick Couvreur
  • Madeleine Besnard
  • Dominique Costantini
  • Ruxandra Gref
Article

DOI: 10.1023/A:1025017502379

Cite this article as:
Lemarchand, C., Couvreur, P., Besnard, M. et al. Pharm Res (2003) 20: 1284. doi:10.1023/A:1025017502379

Abstract

Purpose. The aim of the present study was to develop a new type of core-shell nanoparticles from a family of novel amphiphilic copolymers, based on dextran (DEX) grafted with poly(ε–caprolactone) (PCL) side chains (PCL-DEX).

Methods. A family of PCL-DEX copolymers was synthesized in which both the molecular weight and the proportion by weight of DEX in the copolymer were varied. The nanoparticles were prepared by a technique derived from emulsion-solvent evaporation, during which emulsion stability was investigated using a Turbiscan. The nanoparticle size distribution, density, zeta potential, morphology, and suitability for freeze-drying were determined.

Results. Because of their strongly amphiphilic properties, the PCL-DEX copolymers were able to stabilize o/w emulsions without the need of additional surfactants. Nanoparticles with a controlled mean diameter ranging from 100 to 250 nm were successfully prepared. A mechanism of formation of these nanoparticles was proposed. Zeta potential measurements confirmed the presence of a DEX coating.

Conclusion. A new generation of polysaccharide-decorated nanoparticles has been successfully prepared from a family of PCL-DEX amphiphilic copolymers. They may have potential applications in drug encapsulation and targeting.

nanoparticledextranpoly(epsilon-caprolactone)amphiphilic copolymer

Copyright information

© Plenum Publishing Corporation 2003

Authors and Affiliations

  • Caroline Lemarchand
    • 1
    • 2
  • Patrick Couvreur
    • 1
  • Madeleine Besnard
    • 1
  • Dominique Costantini
    • 2
  • Ruxandra Gref
    • 1
  1. 1.School of PharmacyUMRCNRS 8612Châtenay MalabryFrance
  2. 2.BioAlliance PharmaParisFrance